13 / 20
allied
academies
Virology Research Journal
Volume 1 Issue 4
Vaccines World 2017
Notes:
Page 45
November 09-10, 2017 Vienna, Austria
21
st
World Congress and Exhibition on
VACCINES, VACCINATION & IMMUNIZATION
Tumor liberated protein (TLP) as potential
vaccine for lung cancer patients
Giulio Tarro
Foundation T. & L. de Beaumont Bonelli for cancer research, Italy
T
umor liberated protein (TLP) has been previously
describedas aTAA(complex) present in the sera fromlung
cancer patients with early stage disease. Since early detection
improves overall survival in lung cancer, identification of
screening biomarkers for patients at risk for the development
of this disease represents an important target. Starting from
the peptide epitope RTNKEASI previously isolated from TLP
complexes, we generated a rabbit anti-RTNKEASI serum.
This antiserum detected and immunoprecipitated a 55 kDa
protein band in the lysate of the lung cancer cell line A549.
This protein band was identified as aldehyde dehydrogenase
isoform 1A1 through mass spectrometry, revealing the
molecular nature of at least one component of the previously
described TLP complex. Next, we screened a cohort of 29
lung cancer patients (all histologies), 17 patients with non-
neoplastic lung pathologies and nine healthy donors for the
presence of serum ALDH1A1 and global serum ALDH by
enzyme-linked immunosorbent assay. This analysis indicated
that the presence of ALDH was highly restricted to patients
with lung cancer. Interestingly, the global ALDH test detected
more lung cancer patients compared to the ALDH1A1-
specific test, suggesting that other ALDH isoforms might add
to the sensitivity of the assay. Our data suggest that ALDH
levels may therefore be evaluated as part of a marker panel
for lung cancer screening. Finally, the ability of the immune
system to recognize a TAA, enables the development of a
vaccine approach for preventive and therapeutic application
and represents a main target of this field of research.
giuliotarro@gmail.comVirol Res J 2017, 1:4